Inovio Pharmaceuticals (NASDAQ:INO) Shares Gap Down to $14.46

Inovio Pharmaceuticals Inc (NASDAQ:INO) shares gapped down before the market opened on Wednesday . The stock had previously closed at $14.92, but opened at $14.46. Inovio Pharmaceuticals shares last traded at $13.19, with a volume of 25,597,079 shares changing hands.

A number of equities research analysts have issued reports on INO shares. Maxim Group reaffirmed a “buy” rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday, May 13th. Cantor Fitzgerald raised their target price on shares of Inovio Pharmaceuticals from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. ValuEngine raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Piper Sandler lowered shares of Inovio Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $8.00 target price for the company. in a report on Friday, March 13th. Finally, Royal Bank of Canada lowered shares of Inovio Pharmaceuticals to a “hold” rating in a report on Monday, April 6th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.33.

The company has a 50 day moving average of $11.49 and a 200-day moving average of $6.15. The company has a debt-to-equity ratio of 0.51, a quick ratio of 8.53 and a current ratio of 8.53. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of -12.39 and a beta of 1.34.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.55 million. Inovio Pharmaceuticals had a negative net margin of 4,700.42% and a negative return on equity of 166.85%. During the same period in the prior year, the business earned ($0.30) EPS. On average, research analysts anticipate that Inovio Pharmaceuticals Inc will post -0.74 EPS for the current year.

In other news, Director David B. Weiner sold 3,500 shares of the stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $11.14, for a total value of $38,990.00. Following the transaction, the director now owns 828,610 shares in the company, valued at approximately $9,230,715.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David B. Weiner sold 2,404 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $11.84, for a total value of $28,463.36. Following the completion of the transaction, the director now owns 827,219 shares in the company, valued at approximately $9,794,272.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,404 shares of company stock worth $100,073. Company insiders own 4.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. S.A. Mason LLC purchased a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $26,000. Point72 Hong Kong Ltd purchased a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $37,000. Cubist Systematic Strategies LLC purchased a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $41,000. Levin Capital Strategies L.P. purchased a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $49,000. Finally, US Bancorp DE grew its stake in Inovio Pharmaceuticals by 568.3% during the 1st quarter. US Bancorp DE now owns 6,683 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 5,683 shares during the last quarter. Hedge funds and other institutional investors own 27.83% of the company’s stock.

Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Read More: What is the Rule of 72?

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.